

Docket File Information
SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED: Indiana University Health North Hospital 11700 North Meridian Street Carmel, IN 46032 REPORT NUMBER(S) 2019001	2. NRC/REGIONAL OFFICE Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Rd, Suite 210 Lisle, IL 60532
--	--

3. DOCKET NUMBER(S) 030-37059	4. LICENSE NUMBER(S) 13-32602-01	5. DATE(S) OF INSPECTION May 3, 2019
--------------------------------------	---	---

6. INSPECTION PROCEDURES USED 87131	7. INSPECTION FOCUS AREAS 03.01 - 03.07
--	--

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM CODE(S) 02120	2. PRIORITY 3	3. LICENSEE CONTACT Jennifer Pavich, CNMT	4. TELEPHONE NUMBER (317) 688-3093
---------------------------------	----------------------	--	---

Main Office Inspection Next Inspection Date: 05/03/2022

Field Office Inspection _____

Temporary Job Site Inspection _____

PROGRAM SCOPE

This was a routine, unannounced inspection of a community hospital with authorization to use byproduct materials under 10 CFR Sections 35.100, 35.200, and 35.300. The nuclear medicine department was staffed with two full-time nuclear medicine technologists (NMTs). The NMTs typically administered approximately 130 diagnostic doses monthly, and 8-9 iodine-131 (I-131 in capsule form) therapy dose annually. The diagnostic procedures using technetium-99m (Tc-99m) primarily for cardiac, gastric emptying, HIDA, bone scan, and lung scans using DTPA.

Performance Observations:

The inspection consisted of interviews with select licensee personnel, a review of selected records, and a tour of the nuclear medicine department. The inspector observed preparation and administration of Tc-99m for diagnostic procedures on two patients. The inspector: (1) observed the NMT conduct a physical inventory of sealed sources, and all sources were accounted for; (2) had the NMT demonstrate the package receipt surveys and wipes, dose calibrator constancy check, daily area surveys and weekly wipe tests, and proper handling of radioactive waste and disposal procedures. The inspector reviewed written directives for I-131 hyperthyroid and thyroid cancer therapies.

The inspector reviewed the following records: quarterly program audits, package receipts, waste disposal records, DOT Hazmat training, linearity and accuracy of the dose calibrator, instrument calibration, sealed source leak tests, daily area surveys, and weekly wipe tests. The inspector reviewed the dosimetry records for 2018 and through February 28, 2019 indicating the maximum annual dose to be 71 mrem - DDE; and 776 mrem - SDE. The inspector conducted independent and confirmatory surveys and found no residual contamination or exposures to members of the public in excess of regulatory limits. Interviews with licensee personnel indicated adequate knowledge of radiation safety, emergency procedures, and NRC regulations.

No violations of NRC requirements were identified as a result of this inspection.